Comment on: “Is Robotic Superior to Laparoscopic Approach for Radical Nephroureterectomy with Bladder Cuff Excision in Treating Upper Urinary Tract Urothelial Carcinoma?” by Huang et al.
Restricted accessResearch articleFirst published online October, 2023
Comment on: “Is Robotic Superior to Laparoscopic Approach for Radical Nephroureterectomy with Bladder Cuff Excision in Treating Upper Urinary Tract Urothelial Carcinoma?” by Huang et al.
HuangY-P, HuangEY-H, ChungH-J, et al.Is robotic superior to laparoscopic approach for radical nephroureterectomy with bladder cuff excision in treating upper urinary tract urothelial carcinoma?. J Endourol, 2023; 37(2):139–146; doi: 10.1089/end.2022.0154.
2.
MargulisV, PuligandlaM, TrabulsiEJ, et al.Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma. J Urol, 2020; 203(4):690–698; doi: 10.1097/JU.0000000000000644.
3.
BirtleA, JohnsonM, ChesterJ, et al.Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): A phase 3, open-label, randomised controlled trial. Lancet, 2020; 395(10232):1268–1277; doi: 10.1016/S0140-6736(20)30415-3.
4.
BiyaniCS, PecankaJ, RouprêtM, et al.Intraoperative adverse incident classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. Eur Urol, 2020; 77(5):601–610; doi: 10.1016/j.eururo.2019.11.015.
5.
Dell-KusterS, GomesNV, GawriaL, et al.Prospective validation of classification of intraoperative adverse events (ClassIntra): International, multicentre cohort study. BMJ, 2020; 370:m2917; doi: 10.1136/bmj.m2917.
